Please assess the completion status of the following clinical trial:

Trial Title: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Most recent LVEF to be ≤ 40% by any method within 12 months of randomization.~* High risk heart failure as defined by the following criteria:~A Heart Failure Event in the prior 12 months, defined as any one of the following:~* HF Hospitalization~* Treatment in the Emergency Department (or equivalent) for Heart Failure~* Outpatient treatment for heart failure with intravenous diuretics~AND~* NT-proBNP greater than 2000 pg/mL or BNP greater than 400 pg/mL at any time during the 30 days prior to randomization~* Willing to provide informed consent~Exclusion Criteria:~* Acute coronary syndrome (clinical diagnosis) or cardiac revascularization procedure within 30 days~* Cardiac resynchronization therapy (CRT) within prior 3 months or current plan to implant CRT device~* Active myocarditis, Hypertrophic obstructive cardiomyopathy, pericarditis, or restrictive cardiomyopathy~* Severe stenotic valvular disease~* Anticipated heart transplantation or ventricular assist device within 12 months~* Chronic inotropic therapy~* Complex congenital heart disease~* End stage renal disease with renal replacement therapy~* Non cardiac terminal illness with expected survival less than 12 months~* Women who are pregnant or planning to become pregnant~* Inability to comply with planned study procedures~* Enrollment or planned enrollment in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: EXPERIMENTAL): Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
- Biomarker-Guided Care (Type: EXPERIMENTAL): Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).